Latest Sales Guidance News

New Hope Group exceeded its FY26 coal production and sales guidance, driven by strong performances at Bengalla and New Acland mines, alongside a notable price uplift amid global supply tightness.

Neuren Pharmaceuticals saw a record Q2 with DAYBUE net sales hitting US$125 million, driven by strong uptake of the new STIX formulation. The company upgraded its 2026 royalty guidance following Acadia Pharmaceuticals’ sales boost and awaits key regulatory milestones in Europe and Japan.

KMD Brands expects a 5% rise in FY26 sales and a more than doubling of EBITDA, while planning to divest its Southeast Asian manufacturing facility over the next year.

29Metals reported a mixed June quarter with lower copper but higher zinc production at Golden Grove, steady safety metrics, and ongoing development progress including Xantho Extended mining restart and Gossan Valley first ore on track. Capricorn Copper's restart hinges on regulatory approval and a definitive feasibility study due by year-end.

Atomos Limited has trimmed its FY26 sales guidance to approximately $40 million due to softer end-consumer demand and delayed product shipments, while forecasting EBITDA between $2.5 million and $3.5 million supported by improved margins.

Northern Star Resources has met its revised FY26 gold sales guidance with a strong June quarter performance and remains on track with the KCGM mill expansion. The company also announced the appointment of Suresh Vadnagra as its next CEO, effective October 2026.

TerraCom signals operational recovery with improved coal sales guidance and cost reductions at Blair Athol, while advancing leadership appointments and strategic reviews.

Vita Life Sciences projects a slight increase in H1 2026 sales and stable pre-tax profits, supported by strong markets in Australia and Malaysia/Singapore but offset by regulatory headwinds in China.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.

New Hope Corporation lifted quarterly coal production and sales, cut sustaining capital guidance, and issued $300 million in convertible notes to extend debt maturity to 2032.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Nova Eye Medical has smashed its US sales record in April 2026, prompting an upgrade to its FY26 sales guidance and marking a milestone with positive operational EBITDA.